

EIGHTH EDITION

Immunology & Serology

in Laboratory Medicine

Mary Louise **Turgeon**
EdD, MLS(ASCP)CM

Clinical Laboratory Education Consultant,
Mary L. Turgeon and Associates
Boston, Massachusetts;
St. Petersburg, Florida

Associate Professor
Chair, Department of Medical Laboratory Science (previous)
Northeastern University
Bouve College of Health Professions
Boston, Massachusetts

Professor
Program Director (previous)
Medical Laboratory Technology
Corning Community College
Corning, New York



Elsevier
3251 Riverport Lane
St. Louis, Missouri 63043

IMMUNOLOGY & SEROLOGY IN LABORATORY MEDICINE, EIGHTH EDITION ISBN: 978-0-443-12298-9
Copyright © 2026 by Elsevier Inc. All rights are reserved, including those
for text and data mining, AI training, and similar technologies.

For accessibility purposes, images in electronic versions of this book are accompanied by alt text descriptions provided by Elsevier. For more information, see <https://www.elsevier.com/about/accessibility>.

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notice

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Previous editions copyrighted © 2022, 2018, 2014, 2009, 2003, 1996, 1990.

Content Strategist: Melissa J. Rawe
Senior Content Development Specialist: Shilpa Kumar
Publishing Services Manager: Deepthi Unni
Project Manager: Manchu Mohan
Senior Design Direction: Amy Buxton

Printed in India

Last digit is the print number: 9 8 7 6 5 4 3 2 1



Working together
to grow libraries in
developing countries

www.elsevier.com • www.bookaid.org

CONTENTS

PART I Basic Immunologic Mechanisms

- 1 Foundations of Innate and Adaptive Immune Systems, 2**
- 2 Soluble Mediators of the Immune System, 28**
- 3 Antigens and Antibodies, 47**
- 4 Cellular Activities and Clinical Disorders of Innate and Adaptive Immunity, 67**

PART II The Theory of Immunologic and Serologic Procedures

- 5 Basic Safety in the Immunology-Serology Laboratory, 98**
- 6 Basic Quality Control and Quality Assurance Practices, 107**
- 7 Basic Serologic Laboratory: Techniques and Clinical Applications, 117**
- 8 Precipitation and Particle Agglutination Methods, 128**
- 9 Electrophoresis Techniques and Chromatography, 143**
- 10 Labeling Techniques in Immunoassay, 150**
- 11 Flow Cytometry, 159**
- 12 Molecular Laboratory Techniques, 168**

PART III Immunologic Manifestations of Infectious Diseases

- 13 Infectious Diseases: Overview and TORCH Diseases, 190**
- 14 Streptococcal Infections, 221**
- 15 Syphilis, 228**
- 16 Vector-Borne Diseases, 240**
- 17 Infectious Mononucleosis, 267**
- 18 Viral Hepatitis, 273**

PART IV Immune Disorders

- 19 Primary and Acquired Immunodeficiency Syndromes, 300**
- 20 Hypersensitivity Reactions, 337**
- 21 Plasma Cell Neoplasms and Other Diseases With Paraproteins, 353**
- 22 Tolerance, Autoimmunity, and Autoimmune Disorders, 369**
- 23 Systemic Lupus Erythematosus, 396**
- 24 Rheumatoid Arthritis, 414**

PART V Transplantation and Tumor Immunology

- 25 Transplantation: Human Leukocyte Antigens, Solid Organ, Tissues, and Hematopoietic Stem Cells, 428**
- 26 Tumor Immunology and Applications of Massive Parallel Sequencing/Next-Generation Sequencing, 454**

PART VI Vaccines

- 27 Vaccines: Development and Applications, 478**

Appendix A: Answers to Case Study Multiple-Choice Questions, 500

Appendix B: Answers to Review Questions, 503

Appendix C: Origin and Immunoregulatory Activity of Cytokines, 510

Appendix D: Coronavirus Disease 2019 (COVID-19), 514

Appendix E: Vaccines Licensed for Use in the United States by the Federal Drug Administration, 516

Bibliography, 518

Glossary, 528

Index, 550

Basic Immunologic Mechanisms

Chapter 1: Foundations of Innate and Adaptive Immune Systems, 2

Chapter 2: Soluble Mediators of the Immune System, 28

Chapter 3: Antigens and Antibodies, 47

Chapter 4: Cellular Activities and Clinical Disorders of Innate and Adaptive Immunity, 67

TABLE 1.8 Distribution of Lymphocytes in Lymphoid Organs and Other Tissues^a

Site	CD4+ T Lymphocytes (%)	CD8+ T Lymphocytes (%)	T (T _{reg}) Lymphocytes (%)	B Lymphocytes (%)
Blood	35–60	15–40	0.5–2	5–20
Lymph nodes	50–60	15–20	5–10	20–25
Spleen	50–60	10–15	5–10	40–45

^aApproximate numbers of lymphocytes in different organs of healthy adults.

Adapted from Abbas AK, Lichtman AH, Pillai S: *Basic immunology: functions and disorders of the immune system*, ed 6, 2020, Elsevier; Figs. 1.9 and 1.13 Valiathan R, Deeb K, Diamante M, et al: Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida, *Immunobiology* 219(7):487–496, 2014.




Fig. 1.15 Internal Structure of a Lymph Node. Photomicrography shows a portion of the cortex and medulla. (From Patton KT, Thibodeau GA: *Anthony's textbook of anatomy and physiology*, ed 20, St. Louis, 2013, Elsevier.)




Fig. 1.16 Structure of a Lymph Node. Several afferent valved lymphatics bring lymph to the node. In this example, a single efferent lymphatic leaves the node at a concave area called the hilum. Note that the artery and vein enter and leave at the hilum. (From Patton KT, Thibodeau GA: *Anthony's textbook of anatomy and physiology*, ed 20, St. Louis, 2013, Elsevier.)

L

lag period The period between a stimulus (e.g., antigenic stimulation) and a reaction (e.g., immunoglobulin response).

lambda (λ) light chain One of two types of immunoglobulin light chains that are present in about one-third of all immunoglobulin molecules.

Langerhans cell A macrophage found in the skin.

large granular lymphocyte (LGL) Synonym for natural killer (NK) cell. About 75% of LGLs function as NK cells and appear to account fully for the NK activity in mixed cell populations.

laser Acronym for *light amplification by stimulated emission of radiation*; used in flow cell cytometry to identify cells.

latent Hidden or inactive.

latent infection Persistent infection characterized by periods of reactivation of the signs and symptoms of the disease.

latex agglutination A technique similar to hemagglutination except that smaller, antigen-coated latex particles are substituted for erythrocytes for the detection of antibodies. Antibodies can be absorbed into the latex particles by binding to the Fc region of antibodies, leaving the Fab region free to interact with antigens present in the patient specimen.

lattice formation The establishment of crosslinks between sensitized particles such as erythrocytes.

lattice hypothesis A theoretical step in the production of agglutination.

lecithin A waxy phospholipid.

lecithin pathway A pathway for activation of complement based on the attachment of mannose-binding protein to components of bacterial cell walls.

lesion A localized pathologic change in a bodily organ or tissue, such as a cut, abrasion, or sore.

leukocyte A white blood cell (WBC) that functions in antigen recognition and antibody formation.

leukocyte integrin A glycoprotein on the cell surface of white blood cells.

leukocytosis A marked increase in the total circulating white blood cell concentration.

leukopenia A marked decrease in the total circulating white blood cell concentration.

leukotriene Class of compounds that mediate the inflammatory functions of leukocytes. These substances are a collection of metabolites of arachidonic acid, with powerful pharmacologic effects.

ligand A linking or binding molecule.

ligase chain reaction (LCR) A means of increasing signal probes through the use of an enzyme called ligase, which joins two pairs of probes only after they have bound to a complementary target sequence.

light (L) chain A small chain in an immunoglobulin molecule that is bound to the larger chain by disulfide bonds. There are two types of light chains, kappa and lambda.

light-chain disease (LCD) A dysproteinemia of the monoclonal gammopathy type. In LCD, only kappa or lambda monoclonal light chains, or Bence Jones proteins, are produced.

linear epitope Amino acids that follow one another on a single chain that act as a key antigenic site; linear antigenic determinant.

lipemia Visibly cloudy blood serum.

lipemic Pertaining to lipemia.

lipopolysaccharide (LPS) The major component of some Gram-negative bacterial cell walls that protects them from phagocytosis but activates C3 directly. LPS can also act as a B-cell mitogen.

liposome A particle of fatlike substance held in suspension in tissues.

liposome-enhanced (liposome-enhanced testing) A variation of latex testing.

live, attenuated vaccine A vaccine whose biological activity has not been inactivated, but whose ability to cause disease has been weakened.

localized Confined to a specific area.

localized inflammatory response A tissue reaction confined to a specific area. This response is caused by physical or chemical agents, including microorganisms. The manifestations of the response include redness, tenderness, pain, and swelling.

long terminal redundancy (LTR) A structure that exists at each end of the proviral genome and plays an important role in the control of viral gene expression and the integration of the provirus into the DNA of the host.

lupus anticoagulants Antibodies against substances in the lining of cells. These substances prevent blood clotting in a test tube. They are called phospholipids. People with antibodies to phospholipids (PLs) may have an overly high risk of forming blood clots. Circulating anticoagulants are believed to be associated with the presence of false-positive serologic test results for syphilis.

lupus erythematosus An autoimmune disorder.

luteal phase A period of the menstrual cycle.

luteinizing hormone A hormone associated with ovulation.

Lyme borreliosis A multisystem illness that primarily involves the skin, nervous system, heart, and joints.

Lyme disease A mosquito-borne infectious disease.

lymphadenopathy Disease of the lymph nodes.

lymphoblast The most immature stage of the lymphocyte type of leukocyte.

lymphocyte A small white blood cell found in lymph nodes and circulating blood. Two major populations of lymphocytes are recognized, T and B cells.

lymphocyte recirculation Process that enables lymphocytes to come into contact with processed foreign antigens and disseminate antigen-sensitized memory cells throughout the lymphoid system.

lymphocyte-activating factor See interleukin-1.

lymphocytopenia A severe decrease in the total number of lymphocytes in the peripheral blood.

lymphocytosis A significant increase in the total number of lymphocytes in the peripheral blood.

lymphokine A soluble protein mediator released by sensitized lymphocytes on contact with an antigen. See soluble mediator.

lymphokine-activated killer (LAK) cells A population of natural killer (NK) cells with enhanced cytolytic activity resulting from the addition of IL-2.

lymphoma Solid malignant tumor of the lymph nodes and associated tissues or bone marrow.

lymphopoeitin-1 See interleukin-7.

lymphoproliferative disorder A group of diseases characterized by the proliferation of lymphoid tissues and/or lymphocytes.

lymphosarcoma Malignant neoplastic disorders of the lymphoid tissues, excluding Hodgkin disease.

lyse (lysing) To break apart or dissolve.

lysis Irreversible leakage of cell contents that occurs after membrane damage.

lysozyme (muramidase) An enzyme secreted by macrophages that attacks the cell walls of some bacteria.

lytic Refers to lysis.

M

M protein See monoclonal protein.

macroglobulin A high-molecular-weight protein of the globulin type.

macroglobulinemia See Waldenström primary macroglobulinemia.

macromolecular complex The reaction between the protein being assayed and a specific antiserum.

macrophage A large mononuclear phagocytic cell of the tissues that exists as a wandering or fixed type; lines the capillaries and sinuses of organs such as the bone marrow, spleen, and lymph nodes. This cell phagocytizes, processes, and presents antigens to T cells and is also responsible for removing damaged tissue, cells, bacteria, and other substances from the host.

macrophage migration inhibitory factor (MIF) A lymphocyte product that is chemotactic for monocytes. Other similar factors stimulate monocyte and macrophage functions.

macular lesion A discolored unraised (flat) spot on the skin.

maculopapular A lesion with macular and papular characteristics.

maintenance of self-tolerance The continuing ability to recognize self-antigens.

major histocompatibility complex (MHC) A genetic region in human beings and other mammals responsible for signaling between lymphocytes and antigen-bearing cells. It is also the major determinant of transplant compatibility (or rejection).

malaise A general feeling of tiredness or discomfort.

malignant (malignancy) Cancerous.

malignant neoplasia (malignant neoplasm) A cancerous new growth.

manifestation The development of the signs and symptoms of a disease or disorder.

mannose-binding lectin A pattern recognition molecule of the innate immune system.

mannose-binding lectin pathway A complement activation pathway.

margination The process of white blood cells clinging to the lining of blood vessels.

mass spectrometry An analytic technique that identifies the chemical composition of a

INDEX

A

A. *See* Adenine (A)
Abelson (ABL) kinase inhibitor, 473
ABL kinase inhibitor. *See* Abelson (ABL) kinase inhibitor
Abl proto-oncogene, 460
Abnormal nucleic acid, 471
Abruptio placentae, 345
Absolute lymphocyte count, determination of, 306b
ACA. *See* Acrodermatitis chronica atrophicans (ACA)
Accelerated rejection, 442. *See also* Grafts
Accessory cells. *See* Dendritic cells
Accrediting organizations, 108
Accuracy
definition of, 109b, 110
nonanalytic factors related to testing, 108–109
Acellular pertussis vaccines, 485–487
Acquired immunodeficiency syndrome (AIDS), 313–326
analysis for measuring T cells in, 165
case study of, 334b
classification of, 318
diagnostic evaluation and monitoring of, 322
ARCHITECT HIV Ag/Ab Combo Assay, 326
drug therapy, 327–328
enzyme immunoassays (EIAs), 324
fourth-generation testing, 326
genome testing, 324
HIV-1 antibody assays, 322–324
HIV antigen tests, 324
nucleic acid amplification testing (NAAT), 322–324
OraQuick ADVANCE Rapid HIV-1/2 Antibody Test, 326, 327b
pediatric testing, 326
polymerase chain reaction, 324
quantitative RNA assay, 326
rapid testing, 326, 327b
Western blot, 325–326, 325f
encoding genes and antigens of, 316t
epidemiology of, 316–317
incidence, 306, 317t
infectious patterns, 317–318
etiology of, 313
human T-lymphotropic retrovirus type III (HTLV-III), 313
lymphotoxopathy-associated virus (LAV), 313
replication, 315–316, 316f
viral characteristics of, 314–316
viral genome components, 315t
viral structure of, 314–315, 315f, 315t–316t
HIV-1, 317–318
HIV-2, 318
immunologic manifestations of, 321
cellular abnormalities, 321
core antigen detection, 322, 322f
HIV-1 antibodies, 322
immune system alterations, 321
serologic markers, 322
mode of transmission, 318, 318b
postexposure prophylaxis, 332–334
preexposure prophylaxis, 332, 332b
prevention of, 326
vaccines, 326. *See also* Vaccines
viral transmissions, reduction of, 326

Acquired immunodeficiency syndrome (Continued)
proteins of serodiagnostic importance, 315t
signs and symptoms of, 318–319, 319b
cryptosporidiosis, 320
disease progression, 321
Kaposi sarcoma (KS), 320
non-Hodgkin lymphoma, 320
opportunistic infections, 319–320, 320f, 320t, 320b
testing methods of, 322, 323t
therapeutic monitoring, tests for, 326
CD4+ T lymphocyte testing, 326, 327f
viral load testing, 326
treatments, antiretroviral therapy, 326–332
drug resistance, 327, 329f, 330t–331t, 331–332
entry inhibitors (CCR5 antagonist), 328
fusion inhibitors, 328
highly active antiretroviral therapy (HAART), 319–320
integrase strand transfer inhibitors, 328
investigational drugs, 331–332
nonnucleoside reverse transcriptase inhibitors (NNRTIs), 328
nucleoside reverse transcriptase inhibitors, 328
protease inhibitors, 328
treatments, postexposure prophylaxis (PEP), 332–334
vaccines for, 491–493, 492b–493b
Acquired infection
cytomegalovirus (CMV), 211–212. *See also* Cytomegalovirus (CMV)
toxoplasmosis, 200–205. *See also* Toxoplasmosis
Acrodermatitis chronica atrophicans (ACA), 246
ACTH. *See* Adrenocorticotrophic hormone (ACTH)
Actionable mutations, 459
Activation defects, T-cell, 309
Activator surfaces, 32
Active immunity, 24–25, 25t
Acute conditions, viral hepatitis, 274, 274t. *See also* Viral hepatitis
Acute, infectious mononucleosis, 268
Acute inflammation, 73, 73f
Acute-phase
proteins, 41–45, 41b
applications of, 42b
catabolism, 42
ceruloplasmin, 43
clinically useful, 42t
C-reactive protein (CRP), 42–43
laboratory assessment methods for, 43–45
overview of, 41–42, 42t, 42b
synthesis of, 42
α₁-antitrypsin, 43
reactants, 41, 41b, 43
Acute rejection, 443
Acute respiratory distress syndrome (ARDS), 197
Adaptive immune response, 374
phases of, 80f
Adaptive (acquired) immunity, 6, 23
cell-mediated, 25–26
components of, 24b
features of, 24t

Adaptive (acquired) immunity (Continued)
humoral-mediated, 23
vs. innate immunity, 19–26, 20t
suppression of, 25
types of, 24f
ADCC. *See* Antibody-dependent cell-mediated cytotoxicity (ADCC)
Adenine (A), 169
Adenocarcinomas, 455
Adenomas, 455
Adjuvants, 51, 485. *See also* Antigens (immunogens)
ADN-B. *See* Anti-DNase B (ADN-B)
Adrenal glands, 380
Adrenocorticotrophic hormone (ACTH), as
tumor markers, 469
ADVANCE Rapid HIV-1/2 Antibody Test, 326, 327b
AESOP syndrome, 363
Affinity, 58, 59f
Affymetrix arrays, 183
AFP. *See* Alpha-fetoprotein (AFP)
Agglutination, definition of, 129b
Agglutination inhibition, 131
Agglutination methods, 128–142.e2
antibody influence on, 60–61
case study of, 140b
coagglutination, 131
concepts, 130b
direct bacterial agglutination, 132–133, 132b
flocculation tests, 132
hemagglutination, 133b, 134–138
antibody type and, 134
antigen-antibody ratio and, 134b, 135, 136t
antigenic determinants, 135
enhancing methods, 136
graded reactions, 136, 136t, 137f–138f
lattice formation, 135
mechanisms of, 134–135
microplate reactions of, 136–138
particle charge and, 134
pH of, 135
sensitization, 134–135
temperature and length of incubation, 135
latex, 130–131, 133f–134f, 133t, 133b
nephelometry, 138–140, 138b
advantages and disadvantages of, 139
assays performed by, 138b
clinical application of, 139–140
measuring methods of, 139
optical system of, 139
physical basis of, 139
principle of, 138–139, 138b, 139f
particle, 130, 132t
pregnancy testing, 131
agglutination inhibition, 131
human chorionic gonadotropin, 131
principles of, 129–130, 129f–130f, 130t
procedural protocols, alternative, 131–132, 132b
AIDS. *See* Acquired immunodeficiency syndrome (AIDS)
Aliquot, 121
Alkaline phosphatase (ALP), 152, 154
Alleles
human leukocyte antigen, 430–431, 430t. *See also* Human leukocyte antigens (HLAs)
null, 430

Note: Page numbers followed by “b,” “f” and “t” indicate boxes, figures, and tables respectively.